BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
54.48
-0.07 (-0.13%)
At close: Oct 24, 2025, 4:00 PM EDT
54.99
+0.51 (0.94%)
After-hours: Oct 24, 2025, 7:46 PM EDT
BioMarin Pharmaceutical Revenue
BioMarin Pharmaceutical had revenue of $825.41M in the quarter ending June 30, 2025, with 15.92% growth. This brings the company's revenue in the last twelve months to $3.06B, up 18.36% year-over-year. In the year 2024, BioMarin Pharmaceutical had annual revenue of $2.85B with 17.97% growth.
Revenue (ttm)
$3.06B
Revenue Growth
+18.36%
P/S Ratio
3.40
Revenue / Employee
$1,007,766
Employees
3,040
Market Cap
10.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.85B | 434.69M | 17.97% |
| Dec 31, 2023 | 2.42B | 323.19M | 15.42% |
| Dec 31, 2022 | 2.10B | 249.76M | 13.53% |
| Dec 31, 2021 | 1.85B | -14.18M | -0.76% |
| Dec 31, 2020 | 1.86B | 156.41M | 9.18% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
BMRN News
- 2 days ago - BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET - PRNewsWire
- 25 days ago - BioMarin: Valuation, Growth, And The Pipeline May Outweigh TransCon Competition And Regulatory Risks - Seeking Alpha
- 6 weeks ago - BioMarin Pharmaceutical Inc. (BMRN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment - Benzinga
- 6 weeks ago - BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting - PRNewsWire
- 7 weeks ago - BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism - PRNewsWire
- 7 weeks ago - BioMarin Pharmaceutical Inc. (BMRN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 7 weeks ago - BioMarin Pharmaceutical Inc. (BMRN) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha